Test Type: CHRONIC
Route: DOSED FEED
Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1

Date Report Requested: 06/14/2018 Time Report Requested: 21:33:30 First Dose M/F: 07/27/09 / NA

Lab: BAT

SSAC Males 0-0, 300-0

NTP Study Number: C20614B

Lock Date: 01/10/2012

Cage Range: ALL

Date Range: ALL

Reasons For Removal: 25017 SSAC

Removal Date Range: ALL

Treatment Groups: Include 001 0/0 ppm Include 002 300/0 ppm

Study Gender: Male

TDMSE Version: 2.5.0.0_sfh

PWG Approval Date: NONE

Test Type: CHRONIC
Route: DOSED FEED
Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1

Date Report Requested: 06/14/2018 Time Report Requested: 21:33:30 First Dose M/F: 07/27/09 / NA

Lab: BAT

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD) LAST REMOVAL AT 16 WEEKS

			Males
DOSE	0/0 ppm	300/0 ppm	
Liver			
Clear Cell Focus			
LESION RATES			
OVERALL (a)	1/10 (10%)	1/10 (10%)	
POLY-3 RATE (b)	1/10.00	1/10.00	
POLY-3 PERCENT (g)	10%	10%	
INT SACRIFICE 1	1/10 (10%	1/10 (10%	
TERMINAL (d)	0/0 (0%)	0/0 (0%)	
FIRST INCIDENCE	108 (I)	108 (I)	
STATISTICAL TESTS			
POLY 3		P=0.760	
POLY 1.5		P=0.760	
POLY 6		P=0.760	
COCH-ARM / FISHERS		P=0.763N	
MAX-ISO-POLY-3		P=1.000	

Test Type: CHRONIC
Route: DOSED FEED
Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1

Date Report Requested: 06/14/2018 Time Report Requested: 21:33:30 First Dose M/F: 07/27/09 / NA

Lab: BAT

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD) LAST REMOVAL AT 16 WEEKS

			Males	
DOSE	0/0 ppm	300/0 ppm		
Liver				
Inflammation Focal				
LESION RATES				
OVERALL (a)	9/10 (90%)	7/10 (70%)		
POLY-3 RATE (b)	9/10.00	7/10.00		
POLY-3 PERCENT (g)	90%	70%		
INT SACRIFICE 1	9/10 (90%	7/10 (70%		
TERMINAL (d)	0/0 (0%)	0/0 (0%)		
FIRST INCIDENCE	108 (I)	108 (I)		
STATISTICAL TESTS				
POLY 3		P=0.292N		
POLY 1.5		P=0.292N		
POLY 6		P=0.292N		
COCH-ARM / FISHERS		P=0.291N		
MAX-ISO-POLY-3		P=0.136N		

Test Type: CHRONIC
Route: DOSED FEED
Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1

Date Report Requested: 06/14/2018 Time Report Requested: 21:33:30 First Dose M/F: 07/27/09 / NA

Lab: BAT

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(HSD) LAST REMOVAL AT 16 WEEKS

			Males	
DOSE	0/0 ppm	300/0 ppm		
Liver Necrosis				
LESION RATES				
OVERALL (a)	1/10 (10%)	0/10 (0%)		
POLY-3 RATE (b)	1/10.00	0/10.00		
POLY-3 PERCENT (g)	10%	0%		
INT SACRIFICE 1	1/10 (10%	0/10 (0%		
TERMINAL (d)	0/0 (0%)	0/0 (0%)		
FIRST INCIDENCE	108 (I)			
STATISTICAL TESTS				
POLY 3		P=0.500N		
POLY 1.5		P=0.500N		
POLY 6		P=0.500N		
COCH-ARM / FISHERS		P=0.500N		
MAX-ISO-POLY-3		P=0.158N		

Test Type: CHRONIC
Route: DOSED FEED
Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1

Date Report Requested: 06/14/2018 Time Report Requested: 21:33:30 First Dose M/F: 07/27/09 / NA

Lab: BAT

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.

- (b) Number of tumor-bearing animals/Poly-3 number
- (d) Observed incidence at terminal kill.
- (e) Value of statistic cannot be computed.
- (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to
 - pairwise comparisons between the controls and that dosed group.
- (g) Poly-3 adjusted lifetime tumor incidence.
- (n) No statistics are calculated if all dose groups have fewer than two tumors.
- (I) Interim sacrifice
- (T) Terminal sacrifice
- # Tumor rates based on numbers of animals necropsied.
- * To the right of any statistical result, indicates significance at (P<=0.05).</p>
- ** To the right of any statistical result, indicates significance at (P<=0.01).
- N Indicates a negative trend for all tests
 - The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***